Women account for 50.2% of all U.S. medical residents, achieving a majority share for the first time, according to the Association of American Medical Colleges’ 2025 “Report on Residents.” Women make ...
The Zika virus epidemic that began in Brazil in 2015 and quickly spread to other countries caused an unprecedented flood of ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd.
Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or ...
AB-1009 is an investigational gene therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated. For more information, ...
Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biophar ...
Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Continuous ...
The Shift from Inspiration to Application Early 2026 meeting requests reflect a noticeable shift in audience expectations.
The partnership provides a scalable way to understand and implement NEW player development insights based on how bodies ...
Accepted into StartX Spring 2026, AI-Stroke advances U.S. EMS stroke research with new advisors, clinical studies, and ...
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback